Engineering Precision Nanoparticles for Drug Delivery

Purpose: Nanoparticle (NP) research has generated promising preclinical results, but clinical translation remains limited. A major barrier is the mismatch between one-size-fits-all NP designs and the heterogeneous biological barriers across patients and diseases. Precision medicine offers patient stratification, but precision therapies still face delivery barriers. This review argues that intelligent NP design can overcome these barriers and improve both general and precision therapeutic outcomes. ---

Hypothesis: The review’s central thesis is: if NPs are engineered with specified architectures, material properties, targeting moieties, and responsiveness—tailored to overcome systemic, microenvironmental, and cellular barriers in stratified patient populations—then NP-based delivery can improve the efficacy of precision medicines, including cancer therapy, immunotherapy, and genome editing. ---

Aims: - Review advanced NP designs for both non-personalized and precision medicine applications. - Discuss biological barriers to NP delivery at systemic, microenvironmental, and cellular levels. - Compare lipid-based, polymeric, and inorganic NP platforms. - Examine how NP properties—size, shape, charge, surface coating, targeting, and responsiveness—affect delivery. - Highlight applications in cancer therapy, immunotherapy, and genome editing. - Discuss clinical translation challenges and future directions for precision NP design. ---

Delivery system: Lipid-based NPs: - Liposomes: phospholipid bilayers; carry hydrophilic, hydrophobic, and lipophilic drugs. - Lipid nanoparticles (LNPs): ionizable/cationic lipids, phospholipids, cholesterol, PEGylated lipids; used for nucleic acid delivery, mRNA vaccines. - Examples: Doxil, Onpattro, COVID-19 mRNA vaccines (Moderna, BioNTech/Pfizer). Polymeric NPs: - Nanocapsules, nanospheres, polymersomes, micelles, dendrimers, polyelectrolytes. - Polymers: PLGA, PEG, PEI, PAMAM, poly(β-amino esters), polyelectrolytes. - Payloads: small molecules, proteins, mRNA, siRNA, pDNA, vaccines. Inorganic NPs: - Gold NPs (AuNPs): nanospheres, nanorods, nanostars, nanoshells; photothermal properties. - Iron oxide NPs: superparamagnetic; MRI contrast, drug delivery, hyperthermia. - Silica, calcium phosphate, quantum dots. - Payloads: nucleic acids, proteins, small molecules, imaging agents. Targeting ligands: - Antibodies, carbohydrates (mannose, galactose, dextran), vitamins (folate, vitamin D), aptamers, peptides, transferrin, integrin ligands, cell-penetrating peptides. Responsiveness: - Endogenous triggers: acidic/hypoxic tumor environment, enzyme levels (MMPs), metabolic shifts, redox (GSH). - Exogenous triggers: light, ultrasound, magnetic fields, radiofrequency, force. Payloads: Chemotherapeutics, mRNA, siRNA, pDNA, gRNA, CRISPR-Cas9 RNP, STING agonists, antigens, adjuvants, immunomodulators. ---

Approach: Narrative review of preclinical and clinical literature. No primary experimental groups. Model systems discussed include: - In vitro: Various cell lines for NP uptake, endosomal escape, transfection, and cytotoxicity. - In vivo: Mouse models of cancer, immunotherapy, genome editing; tumor microenvironments; BBB models; mucus barriers. - Clinical: FDA-approved nanomedicines (Doxil, Onpattro, Abraxane, Feraheme, etc.) and clinical trials. - Disease context: Cancer, immunotherapy, genome editing, cystic fibrosis, COVID-19, neurological diseases, autoimmune diseases. ---

Key methods: Techniques highlighted across cited studies: - Flow cytometry for cellular uptake and immune cell activation. - TEM/DLS for NP size, shape, and morphology. - Confocal microscopy for intracellular trafficking and endosomal escape. - MRI/PET for biodistribution and EPR effect quantification. - qPCR/Western blot for gene expression and target validation. - Luciferase reporter assays for transfection efficiency. - Tumor growth inhibition and survival analysis. - Biodistribution and pharmacokinetic studies. - Clinical trial endpoints: efficacy, safety, immune responses. ---

Key results: - Tumor accumulation: Meta-analysis of 232 datasets found that, on average, only 0.7% of injected NP doses reach tumors. - EPR effect variability: Up to 10–15% of injected NPs accumulate at tumor sites in some studies, compared with 0.1% of free drug; however, EPR is highly heterogeneous. - Targeted NP limitation: Antibody-targeted NPs interacted with only 2% of tumor cells in one study. - iCluster system: Inhibited tumor growth by up to 95% in vivo, compared with 10% for free cisplatin. - STING NP: A single dose increased survival for at least 80 days in mice. - Lipoprotein remodeling: Improved NP accessibility to cancer cells 27-fold. - COVID-19 mRNA vaccines: Moderna and BioNTech/Pfizer LNP-mRNA vaccines met primary efficacy endpoints in phase III trials. - FDA-approved nanomedicines: Doxil (1995), Onpattro (2018), Abraxane (2005), Feraheme (2009), and others. ---

Interpretation: The authors conclude that intelligent NP design can improve efficacy in general delivery applications while enabling tailored designs for precision applications. NPs can overcome heterogeneous biological barriers, improve patient stratification, widen accessibility of precision therapeutics, and ultimately improve patient outcomes. The convergence of precision medicine and advanced NP platforms could lead to modular patient therapy designs, pairing optimal therapeutics with optimized delivery platforms. Current clinical successes are largely diagnostic; therapeutic applications in oncology, immunotherapy, and genome editing hold immense potential but require stratified clinical trials. ---

Limitations: - Translational gap: Differences between animal models and humans limit clinical translation. - Patient heterogeneity: Biological barriers vary across patients and diseases; unstratified trials may mask efficacy in subgroups. - EPR controversy: The enhanced permeability and retention effect is highly variable and may not be the main mechanism of tumor accumulation. - Clearance and toxicity: MPS clearance, anti-PEG antibodies, complement activation, and heavy-metal toxicity limit some NPs. - Targeting challenges: Active targeting may increase MPS interactions, off-target delivery, and immunogenicity. - Manufacturing and cost: Advanced NP designs may be expensive and difficult to scale. - Lack of standard metrics: Quantification of NP distribution and delivery is inconsistent. - Clinical trial design: Most NP trials are unstratified; precision NP trials are needed. - As a review: Not a systematic review or meta-analysis; no primary data.